Association between HLA-DP Gene Polymorphisms and Cervical Cancer Risk: A Meta-Analysis

Table 1

Main characteristics of all studies included in the meta-analysis.

First author	Year	Country	Case	Control	Genotyping method	Polymorphisms
Miura K [7]	2016	Japan	214	288	PCR-SBT	DPB102:01, DPB102:02, DPB103:01, DPB104:01, DPB104:02, DPB105:01, DPB113:01, rs4282438
Jia M [8]	2016	China	593	4074	TaqMan assay	rs4282438, rs9277535, rs3117027, rs3077
Yang YC [9]	2015	Taiwan	473	676	PCR, sequencing	DPB102:01, DPB102:02, DPB103:01, DPB104:01, DPB105:01, DPB113:01, rs9277535
Chen D [10]	2014	Sweden	1034	3948	PCR, sequencing	DPB102:01, DPB103:01, DPB104:01, DPB104:02, DPB113:01, rs4282438, rs3117027
Chen D [11]	2013	Sweden	2215	5072	GENios Pro platform	rs3117027
Jiang J [12]	2013	China	2317	2109	TaqMan assay	rs9277535, rs3077
Shi Y [13]	2013	China	5531	10224	Affymetrix Axiom Genome-Wide CHB1 Array	rs4282438
Zhang K [14]	2013	China	831	573	TaqMan assay	rs9277535, rs3077
Ivansson EL [15]	2011	Sweden	1076	1426	Affymetrix Genome-Wide Human SNP Array	DPB102:01, DPB103:01, DPB104:01, DPB104:02, DPB105:01
Liang J [16]	2008	China	126	88	PCR-SBT	DPB102:0102, DPB102:02, DPB103:0101, DPB104:0101, DPB105:01, DPB113:01
Wu Y [17]	2007	China	133	98	PCR-SBT	DPB102:0102, DPB102:02, DPB103:0101, DPB104:0101, DPB104:02, DPB105:01, DPB113:01

PCR-SBT: polymerase chain reaction sequence-based typing; SNP: single nucleotide polymorphisms.